These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17583455)

  • 1. Development of an in silico model for predicting efflux substrates in Caco-2 cells.
    Zhang L; Balimane PV; Johnson SR; Chong S
    Int J Pharm; 2007 Oct; 343(1-2):98-105. PubMed ID: 17583455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery.
    Balimane PV; Patel K; Marino A; Chong S
    Eur J Pharm Biopharm; 2004 Jul; 58(1):99-105. PubMed ID: 15207543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-directional assay samples.
    Smalley J; Kadiyala P; Xin B; Balimane P; Olah T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jan; 830(2):270-7. PubMed ID: 16307910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
    Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
    J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux.
    Desai PV; Sawada GA; Watson IA; Raub TJ
    Mol Pharm; 2013 Apr; 10(4):1249-61. PubMed ID: 23363443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV; Sateesh K; Panchagnula R
    Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay.
    Balimane PV; Chong S
    Int J Pharm; 2005 Sep; 301(1-2):80-8. PubMed ID: 16023314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds.
    Marino AM; Yarde M; Patel H; Chong S; Balimane PV
    Int J Pharm; 2005 Jun; 297(1-2):235-41. PubMed ID: 15907606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport characteristics of rutin deca (H-) sulfonate sodium across Caco-2 cell monolayers.
    He Y; Zeng S
    J Pharm Pharmacol; 2005 Oct; 57(10):1297-303. PubMed ID: 16259758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
    Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
    Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
    Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of P-glycoprotein substrates by a support vector machine approach.
    Xue Y; Yap CW; Sun LZ; Cao ZW; Wang JF; Chen YZ
    J Chem Inf Comput Sci; 2004; 44(4):1497-505. PubMed ID: 15272858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
    Ingels F; Beck B; Oth M; Augustijns P
    Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability.
    Mensch J; Melis A; Mackie C; Verreck G; Brewster ME; Augustijns P
    Eur J Pharm Biopharm; 2010 Mar; 74(3):495-502. PubMed ID: 20067834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model.
    Schrickx J; Fink-Gremmels J
    J Vet Pharmacol Ther; 2007 Feb; 30(1):25-31. PubMed ID: 17217397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human pharmacokinetics--gastrointestinal absorption.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
    Schwab D; Fischer H; Tabatabaei A; Poli S; Huwyler J
    J Med Chem; 2003 Apr; 46(9):1716-25. PubMed ID: 12699389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
    Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
    Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).
    Usansky HH; Sinko PJ
    J Pharmacol Exp Ther; 2005 Jul; 314(1):391-9. PubMed ID: 15833900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.